stockrow
Monday 9 November 2026
Export TRDA’s income statement to Excel — free account
Entrada Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $25.4 million, down 87.9% from fiscal 2024.
- Revenue
- −43.9%
- EPS
- +11.3%
- Free cash flow
- −7.05%
Quarter to September 2026, against a year earlier
4.89
0.34
+7.47%
Follow TRDA
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 2 | 3 |
+8 more TTM periods Free account |
| (59.88%) | (54.09%) | (48.28%) | (39.13%) | ||
| (47.48%) | (44.35%) | (40.42%) | (31.81%) | ||
ROIC |
(2,008.96%) | (1,060.24%) | (697.14%) | (1,009.37%) | |
Return on Tangible Assets |
(88.53%) | (76.38%) | (65.35%) | (49.72%) | |
Average Days of Receivables |
76.91 | 63.56 | 50.06 | 16.90 | |
Free Cash Flow per Share |
(3.22) | (3.18) | (3.15) | (3.13) | |
Free Cash Flow |
(136.33) | (134.35) | (131.64) | (129.55) | |
Capital Expenditures |
(0.01) | 0.32 | 0.06 | (1.04) | |
| Other line items | |||||
Cash ROIC |
(34.84%) | (29.44%) | (25.04%) | (21.50%) | |
Accounts Receivable Turnover |
3.91 | 4.70 | 4.05 | 10.47 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.01 | (0.01) | |
Research and Development Expense of Revenue |
3,388.21% | 3,003.44% | 2,496.50% | 559.65% | |
Selling, General and Administrative Expense of Revenue |
1,015.61% | 863.64% | 712.79% | 161.48% | |
Share Based Compensation of Revenue |
478.50% | 413.32% | 335.76% | 77.14% | |
Operating CF/Net income |
0.84 | 0.81 | 0.79 | 0.89 | |
Depreciation/Fixed assets |
0.00 | 0.24 | 0.17 | 0.06 | |
Capex/Depreciation |
0.00 | 0.23 | 0.05 | (2.45) | |
Revenue per Share |
0.09 | 0.11 | 0.14 | 0.61 | |
Operating CF per Share |
(3.22) | (3.19) | (3.15) | (3.11) | |
Capex per Share |
0.00 | 0.01 | 0.00 | (0.03) | |
Capex to Sales |
0.00 | (0.07) | (0.01) | 0.04 |
Columns are period end dates · fundamentals updated 5 Nov 2026